ANDA 201311, held by P&L Pharmaceuticals. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 201311 (Fexofenadine Hydrochloride), held by P&L Pharmaceuticals, was first approved by FDA on Jul 25, 2012, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fexofenadine Hydrochloride30MG/5ML · suspension;oral | Fexofenadine Hydrochloride | Discontinued |
| Mar 16, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 27, 2016 | Supplement 1Manufacturing | Approved | None posted |
| Jul 25, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters